Acute Lung Injury - Pipeline Review, H2 2013

Global Markets Directs, 'Acute Lung Injury Pipeline Review, H2 2013', provid...
acute Lung Injury Therapeutics Under Investigation By Universities/institutes 14
late Stage Products 16
comparative Analys...
product Description 47
mechanism Of Action 47
r&d Progress 47
respiratory And Inflammatory Diseases Program - Drug Profile...
pancyte - Drug Profile 61
product Description 61
mechanism Of Action 61
r&d Progress 61
ap-301 - Drug Profile 63
product D...
r&d Progress 73
xib-1301 - Drug Profile 74
product Description 74
mechanism Of Action 74
r&d Progress 74
drug Targeting Ur...
sep 27, 2012: Discovery Labs Initiates Research Projects With Research Institutions And Us Government
Agencies To Assess K...
Upcoming SlideShare
Loading in...5
×

Acute Lung Injury - Pipeline Review, H2 2013:Industry Analysis Report

515

Published on

Acute Lung Injury - Pipeline Review, H2 2013:Industry Analysis Report @ http://www.researchmoz.us/acute-lung-injury-pipeline-review-h2-2013-report.html

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
515
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of " Acute Lung Injury - Pipeline Review, H2 2013:Industry Analysis Report "

  1. 1. Acute Lung Injury - Pipeline Review, H2 2013 Global Markets Directs, 'Acute Lung Injury Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acute Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lung Injury. Acute Lung Injury Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope A snapshot of the global therapeutic scenario for Acute Lung Injury. A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Coverage of products based on various stages of development ranging from discovery till registration stages. A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Coverage of the Acute Lung Injury pipeline on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons to buy Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury. Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. table Of Contents table Of Contents 2 list Of Tables 6 list Of Figures 7 introduction 8 global Markets Direct Report Coverage 8 acute Lung Injury Overview 9 therapeutics Development 10 an Overview Of Pipeline Products For Acute Lung Injury 10 acute Lung Injury Therapeutics Under Development By Companies 12 Acute Lung Injury - Pipeline Review, H2 2013
  2. 2. acute Lung Injury Therapeutics Under Investigation By Universities/institutes 14 late Stage Products 16 comparative Analysis 16 mid Clinical Stage Products 17 comparative Analysis 17 early Clinical Stage Products 18 comparative Analysis 18 discovery And Pre-clinical Stage Products 19 comparative Analysis 19 acute Lung Injury Therapeutics - Products Under Development By Companies 20 acute Lung Injury Therapeutics - Products Under Investigation By Universities/institutes 21 companies Involved In Acute Lung Injury Therapeutics Development 22 glaxosmithkline Plc 22 quark Pharmaceuticals, Inc. 23 discovery Laboratories, Inc. 24 silence Therapeutics Plc. 25 altor Bioscience Corporation 26 mondobiotech Holding Ag 27 polyphor Ltd. 28 implicit Bioscience Limited 29 kyorin Pharmaceutical Co., Ltd. 30 techpool Bio-pharma Co., Ltd. 31 mayo Clinic 32 faron Pharmaceuticals, Ltd. 33 apeptico Forschung Und Entwicklung Gmbh 34 acute Lung Injury - Therapeutics Assessment 35 assessment By Monotherapy Products 35 assessment By Route Of Administration 36 assessment By Molecule Type 38 drug Profiles 41 pol-6014 - Drug Profile 41 product Description 41 mechanism Of Action 41 r&d Progress 41 dilmapimod - Drug Profile 43 product Description 43 mechanism Of Action 43 r&d Progress 43 lucinactant - Drug Profile 45 product Description 45 mechanism Of Action 45 r&d Progress 45 alt-836 - Drug Profile 47 Acute Lung Injury - Pipeline Review, H2 2013
  3. 3. product Description 47 mechanism Of Action 47 r&d Progress 47 respiratory And Inflammatory Diseases Program - Drug Profile 49 product Description 49 mechanism Of Action 49 r&d Progress 49 krp-109 - Drug Profile 50 product Description 50 mechanism Of Action 50 r&d Progress 50 gsk-2586881 - Drug Profile 51 product Description 51 mechanism Of Action 51 r&d Progress 51 etanercept - Drug Profile 52 product Description 52 mechanism Of Action 52 r&d Progress 52 atu-111 - Drug Profile 53 product Description 53 mechanism Of Action 53 r&d Progress 53 interferon Beta-1a - Drug Profile 54 product Description 54 mechanism Of Action 54 r&d Progress 54 interferon Beta-1a - Drug Profile 56 product Description 56 mechanism Of Action 56 r&d Progress 56 aspirin - Drug Profile 58 product Description 58 mechanism Of Action 58 r&d Progress 58 rosuvastatin Calcium - Drug Profile 59 product Description 59 mechanism Of Action 59 r&d Progress 59 atu-134 - Drug Profile 60 product Description 60 mechanism Of Action 60 r&d Progress 60 Acute Lung Injury - Pipeline Review, H2 2013
  4. 4. pancyte - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 ap-301 - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 gsk-1995057 - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 ct-2009 - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 daskloster-1000-04 - Drug Profile 67 product Description 67 mechanism Of Action 67 r&d Progress 67 daskloster-014101 - Drug Profile 68 product Description 68 mechanism Of Action 68 r&d Progress 68 isoflurane - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 t-0901317 - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 drug Targeting Leptin - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 stromal Cell Therapy For Acute Lung Injury - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 tp-405 - Drug Profile 73 product Description 73 mechanism Of Action 73 Acute Lung Injury - Pipeline Review, H2 2013
  5. 5. r&d Progress 73 xib-1301 - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 drug Targeting Urokinase Plasminogen Activator - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 mesenchymal Stem Cells - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 drug Inhibiting Igf-1r - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 tat-snap-23 - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 rpai-1 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 s-1226 - Drug Profile 80 product Description 80 mechanism Of Action 80 r&d Progress 80 s-1229 - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 acute Lung Injury Therapeutics - Drug Profile Updates 82 acute Lung Injury Therapeutics - Discontinued Products 90 acute Lung Injury Therapeutics - Dormant Products 91 acute Lung Injury - Product Development Milestones 92 featured News & Press Releases 92 oct 08, 2013: Discovery Labs Announces Notice Of Allowance For A U.s. Patent Supporting The Aerosurf Development Program 92 sep 09, 2013: New Data From The Ali/ards Fpcli001 Study Presented At The 2013 European Respiratory Society Meeting 92 nov 01, 2012: Faron Pharma Receives 375,000 Grant From Tekes For Traumakine Program 93 Acute Lung Injury - Pipeline Review, H2 2013
  6. 6. sep 27, 2012: Discovery Labs Initiates Research Projects With Research Institutions And Us Government Agencies To Assess Kl(4) Surfactant Utility In Acute Lung Injury 93 sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 94 may 21, 2012: Faron Pharma Announces Presentation Of New Data From Ali/ards Fpcli001 Study At 2012 Americanthoracic Society Meeting 95 jan 20, 2012: Carolus Therapeutics Reports Publication Of Preclinical Data For Ct-2009 Supporting Development In Acute Lung Injury 95 dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase Iia Study In Acute Lung Injury Patients 96 nov 08, 2011: Silence Provides Development Update Of Atu134 96 oct 07, 2011: Faron Completes Phase I/ii Clinical Trial With Fp-1201 In Acute Lung Injuries 97 appendix 98 methodology 98 coverage 98 secondary Research 98 primary Research 98 expert Panel Validation 98 contact Us 99 disclaimer 99 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Acute Lung Injury - Pipeline Review, H2 2013

×